Osteoclast activated FoxP3 + CD8 + T-cells suppress bone resorption in vitro

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Buchwald, Zachary S ^a   Kiesel, Jennifer R ^a   DiPaolo, Richard ^a   Pagadala, Meghana S ^a   Aurora, Rajeev ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; CYTOKINE; ENHANCED GREEN FLUORESCENT PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; GREEN FLUORESCENT PROTEIN; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PRIMER DNA; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INTERACTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOSKELETON; FEEDBACK SYSTEM; FOXP3+ CD8+ T LYMPHOCYTE; IMMUNE SYSTEM; IMMUNOSTIMULATION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OSTEOCLAST ACTIVITY; OSTEOLYSIS; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; C57BL MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE MUTANT; OSTEOCLAST; PATHOPHYSIOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERODIAGNOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE RESORPTION; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CYTOKINES; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GREEN FLUORESCENT PROTEINS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTRALIZATION TESTS; OSTEOCLASTS; RANK LIGAND; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84862001747     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038199     Document Type: Article

References (101)

1. Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA, (2009) Local communication on and within bone controls bone remodeling. Bone 44: 1026-1033.
2. Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, et al. (1999) Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. Bone 25: 517-523.
3. Takami M, Woo JT, Nagai K, (1999) Osteoblastic cells induce fusion and activation of osteoclasts through a mechanism independent of macrophage-colony-stimulating factor production. Cell Tissue Res 298: 327-334.
4. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, et al. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345-357.
5. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, et al. (1999) Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 190: 1741-1754.
6. Arron JR, Choi Y, (2000) Bone versus immune system. Nature 408: 535-536.
7. David JP, (2007) Osteoimmunology: a view from the bone. Adv Immunol 95: 149-165.
8. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, et al. (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203: 2673-2682.
9. Takayanagi H, (2005) Osteoimmunological insight into bone damage in rheumatoid arthritis. Mod Rheumatol 15: 225-231.
10. Taubman MA, Valverde P, Han X, Kawai T, (2005) Immune response: the key to bone resorption in periodontal disease. J Periodontol 76: 2033-2041.
11. Teng YT, (2006) Protective and destructive immunity in the periodontium: Part 2-T-cell-mediated immunity in the periodontium. J Dent Res 85: 209-219.
12. Theill LE, Boyle WJ, Penninger JM, (2002) RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 20: 795-823.
13. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, et al. (2006) Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 24: 33-63.
14. Mossetti G, Rendina D, De Filippo G, Viceconti R, Di Domenico G, et al. (2005) Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment. Bone 36: 549-554.
15. Rodan GA, Martin TJ, (2000) Therapeutic approaches to bone diseases. Science 289: 1508-1514.
16. Novack DV, Teitelbaum SL, (2008) The osteoclast: friend or foe? Annu Rev Pathol 3: 457-484.
17. Pacifici R, (2008) Estrogen deficiency, T cells and bone loss. Cell Immunol 252: 68-80.
18. Khattri R, Cox T, Yasayko SA, Ramsdell F, (2003) An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4: 337-342.
19. van der Vliet HJ, Nieuwenhuis EE, (2007) IPEX as a result of mutations in FOXP3. Clin Dev Immunol 2007 89017.
20. Schubert LA, Jeffery E, Zhang Y, Ramsdell F, Ziegler SF, (2001) Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem 276: 37672-37679.
21. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, et al. (2001) Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27: 68-73.
22. Fontenot JD, Gavin MA, Rudensky AY, (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330-336.
23. Hori S, Nomura T, Sakaguchi S, (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
24. Huter EN, Punkosdy GA, Glass DD, Cheng LI, Ward JM, et al. (2008) TGF-beta-induced FoxP3+ regulatory T cells rescue scurfy mice. Eur J Immunol 38: 1814-1821.
25. Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA, (2004) Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 172: 5213-5221.
26. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, et al. (1998) Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10: 1969-1980.
27. Sakaguchi S, (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345-352.
28. Asseman C, Read S, Powrie F, (2003) Colitogenic Th1 cells are present in the antigen-experienced T cell pool in normal mice: control by CD4+ regulatory T cells and IL-10. J Immunol 171: 971-978.
29. Li MO, Sanjabi S, Flavell RA, (2006) Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and-independent mechanisms. Immunity 25: 455-471.
30. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA, (2006) Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24: 99-146.
31. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, et al. (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450: 566-569.
32. Paterson AM, Sharpe AH, (2010) Taming tissue-specific T cells: CTLA-4 reins in self-reactive T cells. Nat Immunol 11: 109-111.
33. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ, (2007) CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 8: 1353-1362.
34. Shevach EM, (2006) From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25: 195-201.
35. Konya C, Goronzy JJ, Weyand CM, (2009) Treating autoimmune disease by targeting CD8(+) T suppressor cells. Expert Opin Biol Ther 9: 951-965.
36. Suzuki M, Konya C, Goronzy JJ, Weyand CM, (2008) Inhibitory CD8+ T cells in autoimmune disease. Hum Immunol 69: 781-789.
37. Waschbisch A, Schwab N, Ruck T, Stenner MP, Wiendl H, (2010) FOXP3+ T regulatory cells in idiopathic inflammatory myopathies. J Neuroimmunol 225: 137-142.
38. Sharabi A, Mozes E, (2008) The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cells. J Immunol 181: 3243-3251.
39. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, et al. (2007) CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 13: 6947-6958.
40. Singh RP, La Cava A, Wong M, Ebling F, Hahn BH, (2007) CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. J Immunol 178: 7649-7657.
41. Tsai S, Shameli A, Yamanouchi J, Clemente-Casares X, Wang J, et al. (2010) Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 32: 568-580.
42. Kiesel J, Miller C, Abu-Amer Y, Aurora R, (2007) Systems level analysis of osteoclastogenesis reveals intrinsic and extrinsic regulatory interactions. Dev Dyn 236: 2181-2197.
43. Li H, Hong S, Qian J, Zheng Y, Yang J, et al. (2010) Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood 116: 210-217.
44. Kiesel JR, Buchwald ZS, Aurora R, (2009) Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells. J Immunol 182: 5477-5487.
45. Takayanagi H, Kim S, Taniguchi T, (2002) Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res 4 (Suppl 3): S227-232.
46. Fox SW, Chambers TJ, (2000) Interferon-gamma directly inhibits TRANCE-induced osteoclastogenesis. Biochem Biophys Res Commun 276: 868-872.
47. van't Hof RJ, Ralston SH, (1997) Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity. J Bone Miner Res 12: 1797-1804.
48. Axmann R, Herman S, Zaiss M, Franz S, Polzer K, et al. (2008) CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 67: 1603-1609.
49. Zaiss MM, Axmann R, Zwerina J, Polzer K, Guckel E, et al. (2007) Treg cells suppress osteoclast formation: A new link between the immune system and bone. Arthritis Rheum 56: 4104-4112.
50. Nagahama K, Aoki K, Nonaka K, Saito H, Takahashi M, et al. (2004) The deficiency of immunoregulatory receptor PD-1 causes mild osteopetrosis. Bone 35: 1059-1068.
51. Cheung J, Mak YT, Papaioannou S, Evans BA, Fogelman I, et al. (2003) Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J Endocrinol 177: 423-433.
52. Haribhai D, Lin W, Relland LM, Truong N, Williams CB, et al. (2007) Regulatory T cells dynamically control the primary immune response to foreign antigen. J Immunol 178: 2961-2972.
53. Lin W, Haribhai D, Relland LM, Truong N, Carlson MR, et al. (2007) Regulatory T cell development in the absence of functional Foxp3. Nat Immunol 8: 359-368.
54. Chen W, Jin W, Hardegen N, Lei KJ, Li L, et al. (2003) Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198: 1875-1886.
55. Davidson TS, DiPaolo RJ, Andersson J, Shevach EM, (2007) Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells. J Immunol 178: 4022-4026.
56. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, et al. (2004) Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172: 5149-5153.
57. Oursler MJ, (1994) Osteoclast synthesis and secretion and activation of latent transforming growth factor beta. J Bone Miner Res 9: 443-452.
58. Bonewald LF, Oreffo RO, Lee CH, Park-Snyder S, Twardzik D, et al. (1997) Effects of retinol on activation of latent transforming growth factor-beta by isolated osteoclasts. Endocrinology 138: 657-666.
59. Centrella M, McCarthy TL, Canalis E (1989) Effects of transforming growth factors on bone cells. Connect Tissue Res 20: 267-275.
60. Dallas SL, Rosser JL, Mundy GR, Bonewald LF, (2002) Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 277: 21352-21360.
61. Fuller K, Lean JM, Bayley KE, Wani MR, Chambers TJ, (2000) A role for TGFbeta(1) in osteoclast differentiation and survival. J Cell Sci 113 (Pt 13): 2445-2453.
62. Filgueira L, (2004) Fluorescence-based staining for tartrate-resistant acidic phosphatase (TRAP) in osteoclasts combined with other fluorescent dyes and protocols. J Histochem Cytochem 52: 411-414.
63. Kohara H, Kitaura H, Fujimura Y, Yoshimatsu M, Morita Y, et al. (2011) IFN-gamma directly inhibits TNF-alpha-induced osteoclastogenesis in vitro and in vivo and induces apoptosis mediated by Fas/Fas ligand interactions. Immunol Lett 137: 53-61.
64. Huang X, Yokota T, Iwata J, Chai Y, (2011) Tgf-beta-mediated FasL-Fas-Caspase pathway is crucial during palatogenesis. J Dent Res 90: 981-987.
65. Zhang H, Hile KL, Asanuma H, Vanderbrink B, Franke EI, et al. (2011) IL-18 mediates proapoptotic signaling in renal tubular cells through a Fas ligand-dependent mechanism. Am J Physiol Renal Physiol 301: F171-178.
66. Novack DV, Faccio R, (2011) Osteoclast motility: putting the brakes on bone resorption. Ageing Res Rev 10: 54-61.
67. Soysa NS, Alles N, Aoki K, Ohya K, (2009) Three-dimensional characterization of osteoclast bone-resorbing activity in the resorption lacunae. J Med Dent Sci 56: 107-112.
68. Luxenburg C, Geblinger D, Klein E, Anderson K, Hanein D, et al. (2007) The architecture of the adhesive apparatus of cultured osteoclasts: from podosome formation to sealing zone assembly. PLoS One 2: e179.
69. Krause CD, Lunn CA, Izotova LS, Mirochnitchenko O, Kotenko SV, et al. (2000) Signaling by covalent heterodimers of interferon-gamma. Evidence for one-sided signaling in the active tetrameric receptor complex. J Biol Chem 275: 22995-23004.
70. Caetano-Lopes J, Canhao H, Fonseca JE, (2009) Osteoimmunology-the hidden immune regulation of bone. Autoimmun Rev 8: 250-255.
71. Lorenzo J, Choi Y, (2005) Osteoimmunology. Immunol Rev 208: 5-6.
72. Takayanagi H, (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7: 292-304.
73. Aandahl EM, Torgersen KM, Tasken K, (2008) CD8+ regulatory T cells-A distinct T-cell lineage or a transient T-cell phenotype? Hum Immunol 69: 696-699.
74. Ablamunits V, Herold KC, (2008) Generation and function of human regulatory CD8+ T cells induced by a humanized OKT3 monoclonal antibody hOKT3gamma1 (Ala-Ala). Hum Immunol 69: 732-736.
75. Allez M, Brimnes J, Dotan I, Mayer L, (2002) Expansion of CD8+ T cells with regulatory function after interaction with intestinal epithelial cells. Gastroenterology 123: 1516-1526.
76. Banham AH, Powrie FM, Suri-Payer E, (2006) FOXP3+ regulatory T cells: Current controversies and future perspectives. Eur J Immunol 36: 2832-2836.
77. Brimnes J, Allez M, Dotan I, Shao L, Nakazawa A, et al. (2005) Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol 174: 5814-5822.
78. Colovai AI, Mirza M, Vlad G, Wang S, Ho E, et al. (2003) Regulatory CD8+CD28- T cells in heart transplant recipients. Hum Immunol 64: 31-37.
79. Correale J, Villa A, (2010) Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis. Ann Neurol 67: 625-638.
80. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, et al. (2007) Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445: 771-775.
81. Jiang H, Chess L, (2008) Qa-1/HLA-E-restricted regulatory CD8+ T cells and self-nonself discrimination: an essay on peripheral T-cell regulation. Hum Immunol 69: 721-727.
82. Kared H, Adle-Biassette H, Fois E, Masson A, Bach JF, et al. (2006) Jagged2-expressing hematopoietic progenitors promote regulatory T cell expansion in the periphery through notch signaling. Immunity 25: 823-834.
83. Kezuka T, Streilein JW, (2000) In vitro generation of regulatory CD8+ T cells similar to those found in mice with anterior chamber-associated immune deviation. Invest Ophthalmol Vis Sci 41: 1803-1811.
84. Meloni F, Morosini M, Solari N, Passadore I, Nascimbene C, et al. (2006) Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 67: 1-12.
85. Niederkorn JY, (2008) Emerging concepts in CD8(+) T regulatory cells. Curr Opin Immunol 20: 327-331.
86. Shevach EM, DiPaolo RA, Andersson J, Zhao DM, Stephens GL, et al. (2006) The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev 212: 60-73.
87. Stephens GL, Andersson J, Shevach EM, (2007) Distinct subsets of FoxP3+ regulatory T cells participate in the control of immune responses. J Immunol 178: 6901-6911.
88. Mayer CT, Floess S, Baru AM, Lahl K, Huehn J, et al. (2011) CD8+ Foxp3+ T cells share developmental and phenotypic features with classical CD4+ Foxp3+ regulatory T cells but lack potent suppressive activity. Eur J Immunol 41: 716-725.
89. Sato K, (2008) Th17 cells and rheumatoid arthritis-from the standpoint of osteoclast differentiation. Allergol Int 57: 109-114.
90. Corthay A, (2009) How do regulatory T cells work? Scand J Immunol 70: 326-336.
91. Pillai MR, Collison LW, Wang X, Finkelstein D, Rehg JE, et al. (2011) The plasticity of regulatory T cell function. J Immunol 187: 4987-4997.
92. Martin TJ, Seeman E, (2008) Bone remodelling: its local regulation and the emergence of bone fragility. Best Pract Res Clin Endocrinol Metab 22: 701-722.
93. Matsuo K, Irie N, (2008) Osteoclast-osteoblast communication. Arch Biochem Biophys 473: 201-209.
94. Adams GB, Scadden DT, (2006) The hematopoietic stem cell in its place. Nat Immunol 7: 333-337.
95. Arai F, Hirao A, Suda T, (2005) Regulation of hematopoiesis and its interaction with stem cell niches. Int J Hematol 82: 371-376.
96. Badillo AT, Flake AW, (2006) The regulatory role of stromal microenvironments in fetal hematopoietic ontogeny. Stem Cell Rev 2: 241-246.
97. Haylock DN, Nilsson SK, (2005) Stem cell regulation by the hematopoietic stem cell niche. Cell Cycle 4: 1353-1355.
98. Kollet O, Dar A, Lapidot T, (2007) The multiple roles of osteoclasts in host defense: bone remodeling and hematopoietic stem cell mobilization. Annu Rev Immunol 25: 51-69.
99. Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, et al. (2006) Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 12: 657-664.
100. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L, (1989) Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol 142: 1536-1541.
101. Tomimori Y, Mori K, Koide M, Nakamichi Y, Ninomiya T, et al. (2009) Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss. J Bone Miner Res 24: 1194-1205.